In conformity with the FSA’s Disclosure and Transparency Rules, the Company notifies the market of the following: As at the date of this announcement, the Company’s issued share capital consists of 27,854,566 ordinary shares with a nominal value of 2 pence each (‘Ordinary Shares’), with voting rights. Download for More Information
Immunodiagnostic Systems Holdings plc (“IDS”), a leading producer of diagnostic testing kits for the clinical and research markets, announces the launch of three newly-developed fully-automated immunoassays for use on the IDS-iSYS Immunoanalyser. Parathyroid hormone (“PTH”) calcium biomarker Insulin-like Growth Factor I (IGF-I) Osteocalcin bone protein These launches bring the IDS-iSYS product range to a total […]
The Company announces that on 18 March 2010, Roger Duggan, Chief Executive Officer, transferred 15,168 ordinary shares of 2 pence each in the Company (‘Ordinary Shares’) to his SIPP at a price of 764.75 pence per share. Following this transfer, Mr Duggan’s notifiable interest in the Company remains unchanged at 2,276,187 Ordinary Shares representing 8.2 […]
